Immunizing mice with DC hyperactivating agents such as LPS and PGPC have been shown to serve as an effective adjuvant to tumour antigens in both therapeutic and prophylactic settings, effectively protecting against various tumours by inducing robust CD8+ T-cell responses [79]. Here, CD8A is linked to neoplasm.